Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PCNA | P12004 | 14/20 | 0.52 |
| ▸ | LIG1 | P18858 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 5/20 | 0.40 |
| ▸ | THRA | P10827 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GABRP | O00591 | 1/20 | 0.40 |
| ▸ | GABRD | O14764 | 1/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1115191 | 0.91 | PCNA (0.52) | PCNALIG1THRBTHRALMNA | |
| SCHEMBL8988780 | 0.85 | PCNA (0.47) | PCNALIG1THRBTHRALMNA | |
| SCHEMBL11226810 | 0.85 | PCNA (0.47) | PCNALIG1THRBTHRALMNA | |
| SCHEMBL31368013 | 0.83 | PCNA (0.71) | PCNALIG1THRBTHRALMNA | |
| SCHEMBL34943 | 0.83 | PCNA (0.71) | PCNALIG1THRBTHRALMNA | |
| SCHEMBL2679290 | 0.82 | PCNA (0.70) | PCNALIG1THRBTHRALMNA | |
| SCHEMBL5501440 | 0.82 | PCNA (0.70) | PCNALIG1THRBTHRALMNA | |
| SCHEMBL9222347 | 0.81 | PCNA (0.44) | PCNALMNACYP2D6TSHR | |
| Sulfuric Acid SCHEMBL2513306 | 0.80 | PCNA (0.67) | PCNALIG1THRBTHRALMNA | |
| SCHEMBL9486078 | 0.76 | PCNA (0.41) | PCNALIG1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080003284-A1 | LEVOTHYROXINE COMPOSITIONS AND METHOS | FRANZ G A | 2008-01-03 | — | — | US | disclosed |
| US-7101569-B2 | Methods of administering levothyroxine pharmaceutical compositions | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2006-09-05 | — | — | US | disclosed |
| EP-1474103-A1 | LEVOTHYROXINE COMPOSITIONS AND METHODS | King Pharmaceuticals, Inc. (US) | 2004-11-10 | — | — | EP | disclosed |
| WO-2004014318-A2 | LEVOTHYROXINE COMPOSITIONS AND METHODS | KING PHARMACEUTICALS, INC. (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2003070217-A1 | LEVOTHYROXINE COMPOSITIONS AND METHODS | KING PHARMACEUTICALS, INC. (US) | 2003-08-28 | — | — | WO | disclosed |
| WO-2003061557-A2 | LEVOTHYROXINE PHARMACEUTICAL COMPOSITIONS, METHODS OF MAKING AND METHODS OF ADMINISTRATION | KING PHARMACEUTICALS, INC. (US) | 2003-07-31 | — | — | WO | disclosed |
| US-6555581-B1 | .00005-5 wt% of a levothyroxine salt, >/= 50 wt% of flat needle shape microcrystalline cellulose with bulk density of .10-.23 g/cm3 and conductivity of < 200 mu s/cm and .5-30 wt% disintegrating agent; immediate release for treating thyroids | JONES PHARMA, INC. | 2003-04-29 | — | — | US | disclosed |
| WO-2003028624-A2 | LEVOTHYROXINE COMPOSITIONS AND METHODS | KING PHARMACEUTICALS, INC (US) | 2003-04-10 | — | — | WO | disclosed |
| WO-2003013441-A2 | LEVOTHYROXINE COMPOSITIONS AND METHODS | KING PHARMACEUTICALS, INC. (US) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080003284-A1 | LEVOTHYROXINE COMPOSITIONS AND METHOS | TPO, TRHDE, THRA | PCNA 4874/4885LIG1 3330/4885THRB 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.